PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Etiology • Symptoms • Pathophysiology • Diagnosis • Epidemiology • Prevention • Treatment • Impact of alcohol consumption on liver cirrhosis PART 06: Pipeline portfolio • Information on pipeline candidates • Clinical trials for liver cirrhosis PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by type of molecule • Biologics • Small molecules PART 09: Market segmentation by types of liver cirrhosis PART 10: Market segmentation by types of liver cirrhosis treatment • Medications to treat causes of liver cirrhosis • Medications to treat complications of liver cirrhosis PART 11: Geographical segmentation • Liver cirrhosis medication market in Americas • Market overview • Market size and forecast • Liver cirrhosis medication market in EMEA • Market overview • Market size and forecast • Liver cirrhosis medication market in APAC • Market overview • Market size and forecast PART 12: Market drivers • High prevalence of liver cirrhosis • Advances in technology • High unmet medical needs • Changes in lifestyle PART 13: Impact of drivers PART 14: Market challenges • Use of alternative therapies • Adverse effects of drugs • Poor patient adherence • Stringent regulatory guidelines PART 15: Impact of drivers and challenges PART 16: Market trends • Rise in public awareness • Increase in R&D • Use of off-label drugs • Patient assistance programs PART 17: Vendor landscape • Competitive scenario • F Hoffmann-La Roche • GlaxoSmithKline • Gilead Sciences • Johnson & Johnson • Merck • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Stages of liver diseases Exhibit 03: Causes of liver cirrhosis Exhibit 04: Diagnosis of liver cirrhosis Exhibit 05: Effect of alcohol consumption on liver cirrhosis Exhibit 06: Pipeline molecules for liver cirrhosis Exhibit 07: Clinical trials by development phase Exhibit 08: Clinical trials by trial status Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions) Exhibit 10: Five forces analysis Exhibit 11: Four main types of liver cirrhosis Exhibit 12: Market share by types of liver cirrhosis Exhibit 13: Types of treatment for liver cirrhosis Exhibit 14: Global liver cirrhosis medication market segment by geography 2015 Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions) Exhibit 16: Liver cirrhosis medication market in Americas ($ millions) Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions) Exhibit 18: Liver cirrhosis medication market in APAC ($ billions) Exhibit 19: Impact of drivers Exhibit 20: Impact of drivers and challenges Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014 Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions) Exhibit 25: F Hoffmann-La Roche: Key takeaways Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014 Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014 Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions) Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014 Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions) Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions) Exhibit 33: Gilead Sciences: Key takeaways Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014 Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014 Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions) Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions) Exhibit 39: Johnson & Johnson: Key takeaways Exhibit 40: Merck: Business segmentation by revenue 2014 Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 42: Merck: Geographical segmentation by revenue 2014 Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions) Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions) Exhibit 45: Merck: Key takeaways

F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, Stempeutics Research.